9156 Safe and long-lasting tumour control with erlotinib in advanced non-small cell lung cancer
Silvia Quadrini(Policlinico Umberto I), Francesco Longo, Rita De Sanctis(Humanitas University), Paolo Grassi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M. DiSeri, R. Sollami, Ester Del Signore(Policlinico Umberto I), Viviana Frantellizzi(Sapienza University of Rome), Bruno Gori(Policlinico Umberto I), Luciano Stumbo(Ospedale San Filippo Neri)
Cited by 0
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
|European Journal of Nuclear Medicine and Molecular Imaging|2019|150